Changes in biochemical parameters related to atherosclerosis after Helicobacter pylori eradication

Alimentary Pharmacology and Therapeutics

Volumn 24, Issue SUPPL.4, 2006, Pages 58-64

  Ando, T ^a   Minami, M ^a   Ishiguro, K ^a   Maeda, O ^a   Watanabe, O ^a   Mizuno, T ^a   Fujita, T ^a   Takahashi, H ^a   Noshiro, M ^a   Goto, H ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CHOLESTEROL; FIBRINOGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERLEUKIN 6; INTERLEUKIN 8; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ATHEROGENESIS; ATHEROSCLEROSIS; BACTERIAL INFECTION; BLOOD ANALYSIS; BODY MASS; BODY WEIGHT; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHEMICAL PARAMETERS; CHOLESTEROL BLOOD LEVEL; CONFERENCE PAPER; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE EXACERBATION; DUODENUM ULCER; FEMALE; HELICOBACTER PYLORI; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; PEPTIC ULCER; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; STOMACH ULCER;

EID: 33846044805     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2006.00026.x     Document Type: Conference Paper

References (50)

1. Danesh J, Collins R, Peto R. Chronic infections and coronary heart disease: is there a link? Lancet 1997; 350: 430-6.
2. Strandberg TE, Tilvis RS. C-reactive protein, cardiovascular risk factors, and mortality in a prospective study in the elderly. Arterioscler Thromb Vasc Biol 2000; 20: 1057-60.
3. Tracy RP, Lemaitre RN, Psaty BM, et al. Relationship of C-reactive protein to risk of cardiovascular disease in the elderly. Results from the Cardiovascular Health Study and the Rural Health Promotion Project. Arterioscler Thromb Vasc Biol 1997; 17: 1121-7.
4. Ridker PM, Buring JE, Shih J, et al. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation 1998; 98: 731-3.
5. Danesh J, Whincup P, Walker M, et al. Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses. Br Med J 2000; 321: 199-204.
6. Danesh J, Collins R, Appleby P, et al. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies. J Am Med Assoc 1998; 279: 1477-82.
7. Markowe HL, Marmot MG, Shipley MJ, et al. Fibrinogen: a possible link between social class and coronary heart disease. Br Med J (Clin Res Ed) 1985; 291: 1312-4.
8. Meade TW, Ruddock V, Stirling Y, et al. Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study. Lancet 1993; 342: 1076-9.
9. Marshall BJ, Warren JR. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet 1984; 1: 1311-5.
10. Blaser MJ, Perez-Perez GI, Kleanthous H, et al. Infection with Helicobacter pylori strains possessing cagA is associated with an increased risk of developing adenocarcinoma of the stomach. Cancer Res 1995; 55: 2111-5.
11. Blaser MJ. Hypothesis: the changing relationships of Helicobacter pylori and humans: implications for health and disease. J Infect Dis 1999; 179: 1523-30.
12. Blaser MJ. Hypotheses on the pathogenesis and natural history of Helicobacter pylori-induced inflammation. Gastroenterology 1992; 102: 720-7.
13. Israel DA, Peek RM. Pathogenesis of Helicobacter pylori-induced gastric inflammation. Aliment Pharmacol Ther 2001; 15: 1271-90.
14. Craig PM, Territo MC, Karnes WE, et al. Helicobacter pylori secretes a chemotactic factor for monocytes and neutrophils. Gut 1992; 33: 1020-3.
15. Mai UE, Perez-Perez GI, Allen JB, et al. Surface proteins from Helicobacter pylori exhibit chemotactic activity for human leukocytes and are present in gastric mucosa. J Exp Med 1992; 175: 517-25.
16. Nielsen H, Andersen LP. Chemotactic activity of Helicobacter pylori sonicate for human polymorphonuclear leucocytes and monocytes. Gut 1992; 33: 738-42.
17. Ando T, Kusugami K, Ohsuga M, et al. Interleukin-8 activity correlates with histological severity in Helicobacter pylori-associated antral gastritis. Am J Gastroenterol 1996; 91: 1150-6.
18. Ando T, Kusugami K, Ohsuga M, et al. Differential normalization of mucosal interleukin-8 and interleukin-6 activity after Helicobacter pylori eradication. Infect Immun 1998; 66: 4742-7.
19. Crabtree JE, Farmery SM, Lindley IJ, et al. CagA/cytotoxic strains of Helicobacter pylori and interleukin-8 in gastric epithelial cell lines. J Clin Pathol 1994; 47: 945-50.
20. Crowe SE, Alvarez L, Dytoc M, et al. Expression of interleukin 8 and CD54 by human gastric epithelium after Helicobacter pylori infection in vitro. Gastroenterology 1995; 108: 65-74.
21. Taub DD, Oppenheim JJ. Chemokines, inflammation and the immune system. Ther Immunol 1994; 1: 229-46.
22. Kishimoto T. The biology of interleukin-6. Blood 1989 74: 1-10.
23. Capurso G, Lahner E, Marcheggiano A, et al. Involvement of the corporal mucosa and related changes in gastric acid secretion characterize patients with iron deficiency anaemia associated with Helicobacter pylori infection. Aliment Pharmacol Ther 2001; 15: 1753-61.
24. Gasbarrini A, Franceschi F, Tartaglione R, et al. Regression of autoimmune thrombocytopenia after eradication of Helicobacter pylori. Lancet 1998; 352: 878.
25. Grimaz S, Damiani D, Brosolo P, et al. Resolution of thrombocytopenia after treatment for Helicobacter pylori: a case report. Haematologica 1999; 84: 283-4.
26. Emilia G, Longo G, Luppi M, et al. Helicobacter pylori eradication can induce platelet recovery in idiopathic thrombocytopenic purpura. Blood 2001; 97: 812-4.
27. Kohda K, Kuga T, Kogawa K, et al. Effect of Helicobacter pylori eradication on platelet recovery in Japanese patients with chronic idiopathic thrombocytopenic purpura and secondary autoimmune thrombocytopenic purpura. Br J Haematol 2002; 118: 584-8.
28. Ando T, Tsuzuki T, Mizuno T, et al. Characteristics of Helicobacter pylori-induced gastritis and the effect of H. pylori eradication in patients with chronic idiopathic thrombocytopenic purpura. Helicobacter 2004; 9: 443-52.
29. Zentilin P, Seriolo B, Dulbecco P, et al. Eradication of Helicobacter pylori may reduce disease severity in rheumatoid arthritis. Aliment Pharmacol Ther 2002; 16: 1291-9.
30. de Luis DA, Varela C, de La Calle H, et al. Helicobacter pylori infection is markedly increased in patients with autoimmune atrophic thyroiditis. J Clin Gastroenterol 1998; 26: 259-63.
31. Ridker PM, Danesh J, Youngman L, et al. A prospective study of Helicobacter pylori seropositivity and the risk for future myocardial infarction among socioeconomically similar U.S. men. Ann Intern Med 2001; 135: 184-8.
32. Majka J, Rog T, Konturek PC, et al. Influence of chronic Helicobacter pylori infection on ischemic cerebral stroke risk factors. Med Sci Monit 2002; 8: CR675-84.
33. Van Lente F. Markers of inflammation as predictors in cardiovascular disease. Clin Chim Acta 2000; 293: 31-52.
34. Niemela S, Karttunen T, Korhonen T, et al. Could Helicobacter pylori infection increase the risk of coronary heart disease by modifying serum lipid concentrations? Heart 1996; 75: 573-5.
35. Strachan DP, Mendall MA, Carrington D, et al. Relation of Helicobacter pylori infection to 13-year mortality and incident ischemic heart disease in the caerphilly prospective heart disease study. Circulation 1998; 98: 1286-90.
36. Azuma T, Suto H, Ito Y, et al. Gastric leptin and Helicobacter pylori infection. Gut 2001; 49: 324-9.
37. Nwokolo CU, Freshwater DA, O'Hare P, et al. Plasma ghrelin following cure of Helicobacter pylori. Gut 2003; 52: 637-40.
38. Breidert M, Miehlke S, Glasow A, et al. Leptin and its receptor in normal human gastric mucosa and in Helicobacter pylori-associated gastritis. Scand J Gastroenterol 1999; 34: 954-61.
39. Goiot H, Attoub S, Kermorgant S, et al. Antral mucosa expresses functional leptin receptors coupled to STAT-3 signaling, which is involved in the control of gastric secretions in the rat. Gastroenterology 2001; 121: 1417-27.
40. Konturek JW, Konturek SJ, Kwiecien N, et al. Leptin in the control of gastric secretion and gut hormones in humans infected with Helicobacter pylori. Scand J Gastroenterol 2001; 36: 1148-54.
41. Schneider R, Bornstein SR, Chrousos GP, et al. Leptin mediates a proliferative response in human gastric mucosa cells with functional receptor. Horm Metab Res 2001; 33: 1-6.
42. Asakawa A, Inui A, Kaga T, et al. Ghrelin is an appetite-stimulatory signal from stomach with structural resemblance to motilin. Gastroenterology 2001; 120: 337-45.
43. Lee HM, Wang G, Englander EW, et al. Ghrelin, a new gastrointestinal endocrine peptide that stimulates insulin secretion: enteric distribution, ontogeny, influence of endocrine, and dietary manipulations. Endocrinology 2002; 143: 185-90.
44. Wang G, Lee HM, Englander E, et al. Ghrelin - not just another stomach hormone. Regul Pept 2002; 105: 75-81.
45. Gokcel A, Gumurdulu Y, Kayaselcuk F, et al. Helicobacter pylori has no effect on plasma ghrelin levels. Eur J Endocrinol 2003; 148: 423-6.
46. Isomoto H, Nakazato M, Ueno H, et al. Low plasma ghrelin levels in patients with Helicobacter pylori-associated gastritis. Am J Med 2004; 117: 429-32.
47. Chimienti G, Russo F, Lamanuzzi BL, et al. Helicobacter pylori is associated with modified lipid profile: impact on Lipoprotein(a). Clin Biochem 2003; 36: 359-65.
48. Patel P, Mendall MA, Carrington D, et al. Association of Helicobacter pylori and Chlamydia pneumoniae infections with coronary heart disease and cardiovascular risk factors. Br Med J 1995; 311: 7114.
49. Nakao M, Malfertheiner P. Growth inhibitory and bactericidal activities of lansoprazole compared with those of omeprazole and pantoprazole against Helicobacter pylori. Helicobacter 1998; 3: 21-7.
50. Dattilo M, Figura N. Helicobacter pylori infection, chronic gastritis, and proton pump inhibitors. J Clin Gastroenterol 1998; 27 (Suppl 1): S163-9.